표피 성장인자 수용체(EGFR) 저해제 시장(2026-2030년)

The global epidermal growth factor receptor (EGFR) inhibitors market is forecasted to grow by USD 11937.9 mn during 2025-2030, accelerating at a CAGR of 10.7% during the forecast period. The report on the global epidermal growth factor receptor (EGFR) inhibitors market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by advancements in combination therapies and regulatory approvals, expansion of precision medicine and diagnostic integration, strategic research and clinical success in addressing resistance.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market size data, segment with regional analysis and vendor landscape in addition to an analysis of the key companies. Reports have historic and forecast data.

Technavio's global epidermal growth factor receptor (EGFR) inhibitors market is segmented as below:

By Indication

• Lung cancer
• Colorectal cancer
• Breast cancer
• Others

By Distribution Channel

• Retail pharmacies
• Hospital pharmacies
• Online pharmacies

By Drug Class

• Small molecule TKIs
• Monoclonal antibodies

Geography

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • The Netherlands
• Asia
• Rest of World (ROW)
• Rest of World (ROW)

This study identifies the advancements in next generation tkis for complex mutations as one of the prime reasons driving the global epidermal growth factor receptor (EGFR) inhibitors market growth during the next few years. Also, shift toward subcutaneous delivery and enhanced patient convenience and integration of ai and advanced biomarker screening will lead to sizable demand in the market.

The report on the global epidermal growth factor receptor (EGFR) inhibitors market covers the following areas:

• Global epidermal growth factor receptor (EGFR) inhibitors market sizing
• Global epidermal growth factor receptor (EGFR) inhibitors market forecast
• Global epidermal growth factor receptor (EGFR) inhibitors market industry analysis

The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading global epidermal growth factor receptor (EGFR) inhibitors market vendors that include Amgen Inc., AstraZeneca Plc, Boehringer Ingelheim GmbH, Bristol Myers Squibb Co., Checkpoint Therapeutics Inc., Eli Lilly and Co., F. Hoffmann La Roche Ltd., Hansoh Pharmaceutical Group Co. Ltd., Hutchison China Meditech Ltd., Jiangsu Hengrui Pharmaceuticals Co. Ltd., Johnson and Johnson Services, Lutris Pharma, Merus N.V., Otsuka Holdings Co. Ltd., Pfizer Inc., Pierre Fabre SA, Puma Biotechnology Inc., Takeda Pharmaceutical Ltd.. Also, the global epidermal growth factor receptor (EGFR) inhibitors market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive primary and secondary research. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.

Table of Contents

1 Executive Summary

• 1.1 Market overview
  • Executive Summary - Chart on Market Overview
  • Executive Summary - Data Table on Market Overview
  • Executive Summary - Chart on Global Market Characteristics
  • Executive Summary - Chart on Market by Geography
  • Executive Summary - Chart on Market Segmentation by Indication
  • Executive Summary - Chart on Market Segmentation by Distribution Channel
  • Executive Summary - Chart on Market Segmentation by Drug Class
  • Executive Summary - Chart on Incremental Growth
  • Executive Summary - Data Table on Incremental Growth
  • Executive Summary - Chart on Company Market Positioning

2 Technavio Analysis

• 2.1 Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
  • Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
• 2.2 Criticality of inputs and Factors of differentiation
• 2.3 Factors of disruption
• 2.4 Impact of drivers and challenges

3 Market Landscape

• 3.1 Market ecosystem
• 3.2 Market characteristics
• 3.3 Value chain analysis

4 Market Sizing

• 4.1 Market definition
• 4.2 Market segment analysis
  • Market segments
• 4.3 Market size 2025
• 4.4 Market outlook: Forecast for 2025-2030

5 Historic Market Size

• 5.1 Global Epidermal Growth Factor Receptor (EGFR) Inhibitors Market 2020 - 2024
  • Historic Market Size - Data Table on Global Epidermal Growth Factor Receptor (EGFR) Inhibitors Market 2020 - 2024 ($ million)
• 5.2 Indication segment analysis 2020 - 2024
  • Historic Market Size - Indication Segment 2020 - 2024 ($ million)
• 5.3 Distribution Channel segment analysis 2020 - 2024
  • Historic Market Size - Distribution Channel Segment 2020 - 2024 ($ million)
• 5.4 Drug Class segment analysis 2020 - 2024
  • Historic Market Size - Drug Class Segment 2020 - 2024 ($ million)
• 5.5 Geography segment analysis 2020 - 2024
  • Historic Market Size - Geography Segment 2020 - 2024 ($ million)
• 5.6 Country segment analysis 2020 - 2024
  • Historic Market Size - Country Segment 2020 - 2024 ($ million)

6 Qualitative Analysis

• 6.1 Impact of AI on Global Epidermal Growth Factor Receptor (EGFR) Inhibitors Market

7 Five Forces Analysis

• 7.1 Five forces summary
  • Five forces analysis - Comparison between 2025 and 2030
• 7.2 Bargaining power of buyers
  • Bargaining power of buyers - Impact of key factors 2025 and 2030
• 7.3 Bargaining power of suppliers
  • Bargaining power of suppliers - Impact of key factors in 2025 and 2030
• 7.4 Threat of new entrants
  • Threat of new entrants - Impact of key factors in 2025 and 2030
• 7.5 Threat of substitutes
  • Threat of substitutes - Impact of key factors in 2025 and 2030
• 7.6 Threat of rivalry
  • Threat of rivalry - Impact of key factors in 2025 and 2030
• 7.7 Market condition

8 Market Segmentation by Indication

• 8.1 Market segments
• 8.2 Comparison by Indication
• 8.3 Lung cancer - Market size and forecast 2025-2030
• 8.4 Colorectal cancer - Market size and forecast 2025-2030
• 8.5 Breast cancer - Market size and forecast 2025-2030
• 8.6 Others - Market size and forecast 2025-2030
• 8.7 Market opportunity by Indication
  • Market opportunity by Indication ($ million)

9 Market Segmentation by Distribution Channel

• 9.1 Market segments
• 9.2 Comparison by Distribution Channel
• 9.3 Retail pharmacies - Market size and forecast 2025-2030
• 9.4 Hospital pharmacies - Market size and forecast 2025-2030
• 9.5 Online pharmacies - Market size and forecast 2025-2030
• 9.6 Market opportunity by Distribution Channel
  • Market opportunity by Distribution Channel ($ million)

10 Market Segmentation by Drug Class

• 10.1 Market segments
• 10.2 Comparison by Drug Class
• 10.3 Small molecule TKIs - Market size and forecast 2025-2030
• 10.4 Monoclonal antibodies - Market size and forecast 2025-2030
• 10.5 Market opportunity by Drug Class
  • Market opportunity by Drug Class ($ million)

11 Customer Landscape

• 11.1 Customer landscape overview
  • Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

12 Geographic Landscape

• 12.1 Geographic segmentation
• 12.2 Geographic comparison
• 12.3 North America - Market size and forecast 2025-2030
  • 12.3.1 US - Market size and forecast 2025-2030
  • 12.3.2 Canada - Market size and forecast 2025-2030
  • 12.3.3 Mexico - Market size and forecast 2025-2030
• 12.4 Europe - Market size and forecast 2025-2030
  • 12.4.1 Germany - Market size and forecast 2025-2030
  • 12.4.2 UK - Market size and forecast 2025-2030
  • 12.4.3 France - Market size and forecast 2025-2030
  • 12.4.4 Italy - Market size and forecast 2025-2030
  • 12.4.5 Spain - Market size and forecast 2025-2030
  • 12.4.6 The Netherlands - Market size and forecast 2025-2030
• 12.5 Asia - Market size and forecast 2025-2030
  • 12.5.1 China - Market size and forecast 2025-2030
  • 12.5.2 India - Market size and forecast 2025-2030
  • 12.5.3 Japan - Market size and forecast 2025-2030
  • 12.5.4 South Korea - Market size and forecast 2025-2030
  • 12.5.5 Indonesia - Market size and forecast 2025-2030
  • 12.5.6 Thailand - Market size and forecast 2025-2030
• 12.6 Rest of World (ROW) - Market size and forecast 2025-2030
  • 12.6.1 Brazil - Market size and forecast 2025-2030
  • 12.6.2 Saudi Arabia - Market size and forecast 2025-2030
  • 12.6.3 UAE - Market size and forecast 2025-2030
  • 12.6.4 Turkey - Market size and forecast 2025-2030
  • 12.6.5 Argentina - Market size and forecast 2025-2030
  • 12.6.6 Colombia - Market size and forecast 2025-2030
  • 12.6.7 South Africa - Market size and forecast 2025-2030
  • 12.6.8 Israel - Market size and forecast 2025-2030
• 12.7 Market opportunity by geography
  • Market opportunity by geography ($ million)
  • Data Tables on Market opportunity by geography ($ million)

13 Drivers, Challenges, and Opportunity

• 13.1 Market drivers
  • Advancements in combination therapies and regulatory approvals
  • Expansion of precision medicine and diagnostic integration
  • Strategic research and clinical success in addressing resistance
• 13.2 Market challenges
  • Resistance mechanisms and need for next generation molecules
  • High costs of therapy and market access limitations
  • Management of treatment induced toxicities and patient compliance
• 13.3 Impact of drivers and challenges
  • Impact of drivers and challenges in 2025 and 2030
• 13.4 Market opportunities
  • Advancements in next generation TKIs for complex mutations
  • Shift toward subcutaneous delivery and enhanced patient convenience
  • Integration of AI and advanced biomarker screening

14 Competitive Landscape

• 14.1 Overview
• 14.2 Competitive Landscape
  • Overview on criticality of inputs and factors of differentiation
• 14.3 Landscape disruption
  • Overview on factors of disruption
• 14.4 Industry risks
  • Impact of key risks on business

15 Competitive Analysis

• 15.1 Companies profiled
  • Companies covered
• 15.2 Company ranking index
  • Company ranking index
• 15.3 Market positioning of companies
  • Matrix on companies position and classification
• 15.4 Amgen Inc.
  • Amgen Inc. - Overview
  • Amgen Inc. - Product / Service
  • Amgen Inc. - Key news
  • Amgen Inc. - Key offerings
  • SWOT
• 15.5 AstraZeneca Plc
  • AstraZeneca Plc - Overview
  • AstraZeneca Plc - Product / Service
  • AstraZeneca Plc - Key news
  • AstraZeneca Plc - Key offerings
  • SWOT
• 15.6 Boehringer Ingelheim GmbH
  • Boehringer Ingelheim GmbH - Overview
  • Boehringer Ingelheim GmbH - Product / Service
  • Boehringer Ingelheim GmbH - Key news
  • Boehringer Ingelheim GmbH - Key offerings
  • SWOT
• 15.7 Bristol Myers Squibb Co.
  • Bristol Myers Squibb Co. - Overview
  • Bristol Myers Squibb Co. - Product / Service
  • Bristol Myers Squibb Co. - Key news
  • Bristol Myers Squibb Co. - Key offerings
  • SWOT
• 15.8 Checkpoint Therapeutics Inc.
  • Checkpoint Therapeutics Inc. - Overview
  • Checkpoint Therapeutics Inc. - Product / Service
  • Checkpoint Therapeutics Inc. - Key offerings
  • SWOT
• 15.9 Eli Lilly and Co.
  • Eli Lilly and Co. - Overview
  • Eli Lilly and Co. - Product / Service
  • Eli Lilly and Co. - Key offerings
  • SWOT
• 15.10 F. Hoffmann La Roche Ltd.
  • F. Hoffmann La Roche Ltd. - Overview
  • F. Hoffmann La Roche Ltd. - Business segments
  • F. Hoffmann La Roche Ltd. - Key news
  • F. Hoffmann La Roche Ltd. - Key offerings
  • F. Hoffmann La Roche Ltd. - Segment focus
  • SWOT
• 15.11 Hutchison China Meditech Ltd.
  • Hutchison China Meditech Ltd. - Overview
  • Hutchison China Meditech Ltd. - Business segments
  • Hutchison China Meditech Ltd. - Key offerings
  • Hutchison China Meditech Ltd. - Segment focus
  • SWOT
• 15.12 Lutris Pharma
  • Lutris Pharma - Overview
  • Lutris Pharma - Product / Service
  • Lutris Pharma - Key offerings
  • SWOT
• 15.13 Merus N.V.
  • Merus N.V. - Overview
  • Merus N.V. - Product / Service
  • Merus N.V. - Key offerings
  • SWOT
• 15.14 Otsuka Holdings Co. Ltd.
  • Otsuka Holdings Co. Ltd. - Overview
  • Otsuka Holdings Co. Ltd. - Business segments
  • Otsuka Holdings Co. Ltd. - Key news
  • Otsuka Holdings Co. Ltd. - Key offerings
  • Otsuka Holdings Co. Ltd. - Segment focus
  • SWOT
• 15.15 Pfizer Inc.
  • Pfizer Inc. - Overview
  • Pfizer Inc. - Business segments
  • Pfizer Inc. - Key news
  • Pfizer Inc. - Key offerings
  • Pfizer Inc. - Segment focus
  • SWOT
• 15.16 Pierre Fabre SA
  • Pierre Fabre SA - Overview
  • Pierre Fabre SA - Product / Service
  • Pierre Fabre SA - Key offerings
  • SWOT
• 15.17 Puma Biotechnology Inc.
  • Puma Biotechnology Inc. - Overview
  • Puma Biotechnology Inc. - Product / Service
  • Puma Biotechnology Inc. - Key offerings
  • SWOT
• 15.18 Takeda Pharmaceutical Ltd.
  • Takeda Pharmaceutical Ltd. - Overview
  • Takeda Pharmaceutical Ltd. - Business segments
  • Takeda Pharmaceutical Ltd. - Key news
  • Takeda Pharmaceutical Ltd. - Key offerings
  • Takeda Pharmaceutical Ltd. - Segment focus
  • SWOT

16 Appendix

• 16.1 Scope of the report
  • Market definition
  • Objectives
  • Notes and caveats
• 16.2 Inclusions and exclusions checklist
  • Inclusions checklist
  • Exclusions checklist
• 16.3 Currency conversion rates for US$
  • Currency conversion rates for US$
• 16.4 Research methodology
  • Research methodology
• 16.5 Data procurement
  • Information sources
• 16.6 Data validation
  • Data validation
• 16.7 Validation techniques employed for market sizing
  • Validation techniques employed for market sizing
• 16.8 Data synthesis
  • Data synthesis
• 16.9 360 degree market analysis
  • 360 degree market analysis
• 16.10 List of abbreviations
  • List of abbreviations